Citi raised the firm’s price target on Caribou Biosciences (CRBU) to $8 from $5 and keeps a Buy rating on the shares, citing “meaningfully increased conviction” in the allogenic CAR-T value proposition following two “strong” data readouts in patients with relapsed or refractory B cell non-Hodgkin lymphoma and with relapsed or refractory multiple myeloma. The results deliver on previously communicated goals to generate continued allogenic efficacy on par with auto CAR-Ts and bispecifics, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences Reports Positive ANTLER Phase 1 Results
- Caribou Biosciences announces results from CaMMouflage Phase 1 trial
- Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel
- Caribou Biosciences’ CRISPR-Edited CAR-T Therapy: A Promising Step in Multiple Myeloma Treatment
- Caribou Biosciences’ Long-Term Study: A Key Update for Investors